NCT00077805已完成4 期
An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 试验地点
- 16
- 主要终点
- Cumulative occurrence of VTE events (deep-vein thrombosis, pulmonary embolism)
研究概览
简要总结
Primary objective:
- To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
Secondary objectives:
- To compare the incidence of VTE between the 2 treatment groups at 30, 60, and 90 days from the time of randomization
- To compare neurologic outcomes between the 2 treatment groups, including incidence of stroke recurrence, rate of stroke progression, and patient functional status, during the 10 ± 4 days of treatment, and after 30, 60, and 90 days from the time of randomization
- To evaluate the safety of using enoxaparin compared to UFH for VTE prevention in patients following acute ischemic stroke
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute ischemic stroke, any territory, with an appropriate neuroradiologic study (head CT scan or brain MRI scan) providing results consistent with non hemorrhagic stroke
- •Onset of symptoms of qualifying stroke within 48 hours prior to randomization. In patients receiving thrombolytic therapy for the acute stroke, such as tissue-type plasminogen activator (tPA), administration of study drug may not start until at least 24 hours after completion of thrombolytic therapy
- •Significant motor impairment of the leg, as indicated by a NIHSS score ≥2 on item 6
- •Inability to walk without assistance
排除标准
- •Females who are pregnant, breast-feeding, or of childbearing potential and not using medically acceptable and effective contraception
- •Clinical evidence of VTE at screening
- •Any evidence of active bleeding on the basis of clinical judgment
- •Prior history of intracranial hemorrhage (including that at screening)
- •Spinal or epidural analgesia or lumbar puncture within the preceding 24 hours
- •Thrombolytic therapy (e.g., tPA) or intra-arterial thrombolytic therapy within the preceding 24 hours.Thrombolytic therapy is permitted for treatment of the acute stroke but must have been completed 24 hours prior to randomization.
- •Comatose at screening (NIHSS score ≥2 on item 1a)
- •Known or suspected cerebral aneurysm or arteriovenous malformation
- •Confirmed malignancy that may pose an increased risk for bleeding or otherwise compromise follow-up or outcome assessment (e.g., lung cancer)
- •Impaired hemostasis, i.e., known or suspected coagulopathy (acquired or inherited); baseline platelet count <100,000/mm3; aPTT 1.5 X the laboratory upper limit of normal; or international normalized ratio(INR) >1.5
- •Major surgery or recent major trauma within the previous 3 months
- •Anticipated need for full-dose treatment with therapeutic levels of an anticoagulant (LMWH, UFH, oral anticoagulant), e.g., for cardiogenic source of embolism or dissection
- •Treatment with a LMWH or UFH at prophylactic dose for more than 48 hours prior to randomization(patients receiving LMWH or UFH less than 48 hours prior to randomization may be randomized)
- •Allergy to heparin or enoxaparin sodium, or known hypersensitivity to heparin, enoxaparin, or pork products
- •History of heparin or enoxaparin induced thrombocytopenia and/or thrombosis (heparin-induced thrombocytopenia [HIT], heparin-associated thrombocytopenia [HAT], or heparin-induced thrombotic thrombocytopenia syndrome [HITTS])
- •History of hypersensitivity to iodinated contrast media and/or iodine
- •Bacterial endocarditis
- •Prosthetic heart valve
- •Known or suspected severe anemia (Hg <10.0 g/dL)
- •Uncontrolled arterial hypertension (systolic blood pressure [BP] >180 mmHg or diastolic BP >100 mmHg) at the time of randomization or clinical hypertensive urgency
- •Any other clinically relevant serious diseases, including severe liver disease or renal failure [creatinine clearance <30 mL/min on at least two occasions].
- •Treatment with other investigational agents or devices within the previous 30 days, planned use of other investigational drugs or devices, or previous enrollment in this study.
结局指标
主要结局
Cumulative occurrence of VTE events (deep-vein thrombosis, pulmonary embolism)
时间窗: 10 ± 4 days following acute ischemic stroke
次要结局
- cumulative VTE events(at 30-day, 60-day and 90-day)
- stroke recurrence, stroke progression, National Institute of Health Stroke Scale (NIHSS) scores(during treatment and follow-up periods)
- Modified Rankin Scale (MRS) scores(at 30-day and 90-day follow-up)
- major & minor hemorrhages(from the inform consent signed up to the end of the study)
- Treatment emergent adverse events (TEAE), serious adverse events (SAE), all-cause mortality(from the inform consent signed up to the end of the study)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
4 期
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged ImmobilizationVenous ThromboembolismNCT00077753Sanofi4,726
已完成
不适用
Prevention of postoperative VTE using Enoxaparin in laparoscopic gastrectomy and colectomy for malignancies.Gastric and colon cancerJPRN-UMIN000011667Gastroenterological Surgery 1 Hokkaido Univ. Graduated School of Medicine450
终止
4 期
Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)Unstable AnginaNCT00518245Canadian Heart Research Centre11
已完成
不适用
The EPPI Trial – Enoxaparin for the Prevention of Preeclampsia and Intrauterine growth restriction – a pilot randomised open-label trial.Intrauterine growth restrictionACTRN12609000699268niversity of Auckland160
已完成
4 期
Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)Acute Coronary SyndromeNCT00077818Sanofi